ClinicalTrials.gg
Not yet recruitingNCT07937748Updated Nov 16, 2026

Filsuvez in Infants With Dystrophic or Junctional Epidermolysis Bullosa

A Phase 1 interventional study of Filsuvez topical gel: 10% birch triterpenes in Dystrophic Epidermolysis Bullosa and Junctional Epidermolysis Bullosa, sponsored by Medical University of South Carolina. Not yet recruiting at 1 site in United States. Open to participants aged 0 Days to 5 Months. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Medical University of South Carolina · Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
0 Days to 5 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States — 13 open to participants now, 17 under way, 4 of them phase 3. Epidermolysis Bullosa Dystrophica · United States.

Planned enrollment
5th of 33
20 · median 8
Started
2027
the only one that year
Phase 1
4 of 46
1 open now
Primary completion
2029-01
later than 13 of 16 live
Registered
46th of 46
by date

Among the 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States, this one is the 5th largest by planned enrollment of the 33 interventional ones that give a count, is the only one that started in 2027, is one of 4 in phase 1, reaches primary completion later than 13 of the 16 other live ones, and was the 46th registered.

Epidermolysis Bullosa Dystrophica

79 studies on the registry are indexed under Epidermolysis Bullosa Dystrophica; 22 are open to participants now.

Browse Epidermolysis Bullosa Dystrophica studies →

Open to participants now

13 of the 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Epidermolysis Bullosa Dystrophica studies recruiting now, 13 (76%) set no upper age limit and 3 (18%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 0 Days to 5 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States, or all of them as a file.
02

Study summary

This pilot study will evaluate the safety and tolerability of Filsuvez, a topical gel, in newborns and infants younger than 6 months with dystrophic or junctional epidermolysis bullosa. Filsuvez is approved for patients 6 months of age and older but has not been studied in this younger population. Participants will receive Filsuvez for 180 days and will be followed with clinical assessments, laboratory testing, caregiver questionnaires, telephone contacts, and standardized photographs. The study will also explore changes in wound size, disease activity, pain, and family burden during and after treatment.

Read the detailed description

Epidermolysis bullosa is a rare genetic disorder characterized by skin fragility, blistering, and chronic wounds. Newborns and young infants with dystrophic or junctional epidermolysis bullosa have limited treatment options and may be at increased risk for infection and other complications. This open-label, multicenter pilot study will enroll up to 20 participants who are 5 months of age or younger at enrollment. Participants will receive topical Filsuvez with standard wound-dressing changes for 180 days. Safety will be monitored through adverse-event and concomitant-medication assessments, clinical evaluations, and laboratory tests including complete blood count, basic metabolic panel, and inflammatory markers. Follow-up assessments include standardized full-body photography, disease activity and body-surface-area assessments, wound measurements, pain assessment, and caregiver-reported family burden. Participants will be followed during treatment and for 180 days after the treatment period.

03

Conditions studied

  • Dystrophic Epidermolysis Bullosa
  • Junctional Epidermolysis Bullosa

Keywords

  • Epidermolysis bullosa
  • Filsuvez
  • Birch triterpenes
  • Infant
  • Neonate
  • Wound healing
  • Skin fragility
04

Who can participate

Ages eligible
0 Days to 5 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed junctional epidermolysis bullosa or dystrophic epidermolysis bullosa diagnosis based on genetic and clinical evaluation.
  2. Newborns and infants aged 5 months or younger at enrollment.
  3. Ability of the parent or legal guardian to complete telephone assessments and comply with study procedures, as determined by the investigator.
  4. Written from the parent or legal guardian.

Exclusion criteria

Exclusion Criteria:

  1. Systemic infection, septicemia, or sepsis at enrollment.
  2. Systemic antibiotics for a wound-related infection within 7 days before enrollment.
  3. Current wound infection.
  4. therapy or systemic treatment that could interfere with wound healing within 30 days before enrollment.
  5. Systemic or topical , except inhaled or ophthalmic steroids, within 2 weeks before enrollment.
  6. Enrollment in another interventional study or treatment with an investigational drug within 4 weeks before enrollment.
  7. therapy or cytotoxic chemotherapy within 60 days before enrollment.
  8. Allergy or to Filsuvez, birch triterpenes, sunflower oil, or another product component.
  9. Severe malnutrition or another condition that may compromise wound healing.
  10. Likely need for major surgery during the study.
  11. Inability to follow study procedures or scheduled follow-up.
  12. Immediate family member of the investigational team.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    Open Label Extension of Filsuvez topical gel: 10% birch triterpenes

    Filsuvez topical gel: 10% birch triterpenes will be applied with a 1mm layer to the affected wound surface and cover the wound dressing. Filsuvez should be applied directly to the dressing so that the topical gel is in direct contact with the wound. Filsuvez can be applied with standard of care bandage changes, at least every 4 days.

    Drug: Filsuvez topical gel: 10% birch triterpenes

Interventions

  • DrugFilsuvez topical gel: 10% birch triterpenes

    Filsuvez topical gel: 10% birch triterpenes w/w in a colorless, slightly yellow gel supplied in 25 mL sterile tubes.

06

What researchers measure

Primary outcomes

  1. the safety and tolerability of Filsuvez

    Our primary objective is to evaluate the safety and tolerability of Filsuvez for neonates and infants under six months of age with dystrophic or junctional EB (DEB or JEB). We plan to conduct monthly phone calls to assess adverse events and concomitant meds.

    Time frame: 450 days-including follow up

Secondary outcomes

  1. Evaluate preliminary efficacy and quantify the reduction in wound size and burden from baseline to 45, 90, and 180 days

    Our secondary objective is to evaluate preliminary efficacy and quantify the reduction in wound size and burden from baseline to 45, 90, and 180 days during the treatment period using full body photographic skin assessment, ensuring that a ruler with cm is included in the photograph for later analysis.

    Time frame: 180 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jan 1, 2029
CompletionEst.
Jan 1, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937748
Collaborators
Chiesi USA, Inc.
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 1, 2029 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Kennedy Louise McLeod
Contact
mcleodke@musc.edu
843-792-4091
Lara Wine Lee, MD, PhD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion